Apparently results from a phase II study were encouraging and they are starting a phase III study:
Details about the trial are here:
Apparently results from a phase II study were encouraging and they are starting a phase III study:
Details about the trial are here:
Thanks for that Elodie, always appreciate the info you post.
Kind Regards
Karen
Thank you for sharing.
I just want to double check with you to make sure I understand right. Is patient allowed to participate in the trial for TH-302 alone if he got ifo-doxo two years ago?
Thank you in advance.
Townclerk, how is your husband doing now? I just found out that Merck decided not to pursue TH-302 (evofosfamide) further:
http://www.emdgroup.com/emd/media/news_releases/news_releases.html
I was really hoping this drug would become another option :-( I am wondering what happens to the patients who are still on it...
The results of the TH-302 trial were announced and they are very disappointing:
http://www.targetedonc.com/news/maestro-trial-shows-evofosfamide-provides-little-benefit-in-sts
Combining Evofosfamide (TH-302) and Doxorubicin turned out to be inefficient for soft tissue sarcoma except for synovial sarcoma in a phase 3 trial where overall survival for the combination was 22.1 months compare to 9.4 months with Doxorubicin alone:
An additional trial would be needed to confirm that it wasn’t just the luck of the draw…